Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial -

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
Information type: Randomised controlled trials
Source: Journal of the American Medical Association
Specialities: Endocrine system disorders | Musculo-skeletal disorders
Summary
Study (n=2463) found at 18 months, alaboparatide reduced the risk of vertebral fractures (RR 0.14, 95% CI 0.05-0.39) and nonvertebral fracture (HR 0.57, 0.32-1.00) vs. placebo. Further research is needed to establish efficacy vs. other osteoporosis treatments.
UKMi comment
Abaloparatide is a synthetic peptide that engages the parathyroid hormone receptor (PTH1 receptor), which is currently in phase 3 studies.

An editorial comments on limitations of this study such as use of open label teriparatide in this study in its commercial packaging.
Related links: Editorial